In The Next Issue
The next
issue of Cancer Control: Journal of the Moffitt Cancer Center
will focus
on new paradigms for anticancer drugs. Among the topics and authors are:
"Evaluation of Palliative Endpoints in Oncology
Clinical Trials," by Paul B. Jacobsen, PhD, and Michael A. Weitzner,
MD, of the H. Lee Moffitt Cancer Center & Research Institute
"Review of Three New Agents That Target Angiogenesis,
Matrix Metalloproteinases, and Cyclin-Dependent Kinases," by Richard
M. Lush, PhD, of the H. Lee Moffitt Cancer Center & Research Institute, and
Michelle A. Rudek, BS, and William D. Figg, PharmD, of the Division of Clinical
Sciences at the National Cancer Institute
"Pharmacology of Chemotherapy
in the Older Cancer Patient," by Lodovico Balducci, MD, of the H. Lee Moffitt
Cancer Center & Research Institute
"Signal Transducers and
Activators of Transcription: Novel Targets for Anticancer Therapeutics,"
by Tammy Bowman, PhD, Hua Yu, PhD, Saïd Sebti, PhD, William Dalton, PhD,
MD, and Richard Jove, PhD, of the H. Lee Moffitt Cancer Center & Research
Institute
"Angiogenesis and Cancer
Control: From Concept to Therapeutic Trial," by
Steven Brem, MD, of the H. Lee Moffitt Cancer Center & Research Institute
The regular departments of Cancer Control
will feature Imaging in Oncology, Supportive Care, Ten Best Readings on Anticancer
Drugs, Clinical Research Protocols, Pathology Update, and Oncology Pharmacotherapy.
Also included will be Presentation Highlights from the 1999 Joint Cancer Conference.